Journal Article Review Epublish
PubMed: 40827265 DOI: 10.2147/JIR.S530754
Role of Interleukin-6 in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Focus on the JAK/STAT Pathway and Macrophage Polarization.
J Inflamm Res 18:10953-10967
Authors: Zhiping Yu, Ji Liu, Letian Chen, Junping Xie
Affiliations
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China. Department of Respiratory and Critical Care Medicine, Yingtan People's Hospital, Yingtan, Jiangxi, People's Republic of China.
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
- Department of Respiratory and Critical Care Medicine, Yingtan People's Hospital, Yingtan, Jiangxi, People's Republic of China.
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by chronic synovitis and extra-articular manifestations (EAMs), with interstitial lung disease (ILD) being a leading cause of mortality. Interleukin-6 (IL-6), a pivotal cytokine in RA pathogenesis, drives both articular and pulmonary inflammation through its involvement in immune dysregulation and fibrotic processes. This review elucidates the molecular mechanisms by which IL-6 contributes to rheumatoid arthritis-associated interstitial lung disease (RA-ILD) progression, particularly via the Janus kinases (JAK)/signal transducers and activators of transcription (STAT) signaling pathway and macrophage polarization. Additionally, we objectively evaluate current and emerging therapeutic strategies targeting IL-6 and downstream pathways.
MeSH
Lung, Macrophages, Arthritis, Interleukin-6, Arthritis, Rheumatoid, Janus Kinases, Lung Diseases, Lung Diseases, Interstitial